高效疗法作为儿童期起病多发性硬化的一线治疗
这项在法国36个多发性硬化中心开展的回溯性队列研究纳入530例儿童期起病复发缓解型多发性硬化患者,比较高效疗法与中等疗效疗法作为初始治疗与疾病活动的关系。高效疗法使首次复发风险降低54%(校正HR 0.46,95%CI 0.31-0.67,P<.001),并持续5年,MRI活动也得到确认(校正OR 0.34,95%CI 0.18-0.66,P=.001),耐受性更好。
要点
- 高效疗法较中等疗效疗法使首次复发风险降低54%,且持续5年。
- 高效疗法组MRI活动更低(校正OR 0.34),耐受性更好。
- 中等疗效疗法2年停药风险是高效疗法的近6倍(HR 5.97)。
核心结论
- 与中等疗效疗法相比,儿童期起病多发性硬化初始高效疗法与首次复发风险降低相关,2年内即可获得最佳结局,并与较低的治疗转换率和更好的中期耐受性相关。
- 作者认为这些发现提示应优先考虑初始高效疗法,但需要长期安全性研究。
研究设计与样本
- 回溯性队列研究,纳入2010年1月1日至2022年12月8日期间法国36个多发性硬化中心(OFSEP队列)中未接受过治疗、在成年之前接受首个高效疗法或中等疗效疗法且至少有一次随访临床 visit 的复发缓解型儿童期起病多发性硬化患儿。
- 共纳入530例患者(平均[SD]年龄16.0[1.8]岁;女性364例[68.7%]),中位随访5.8年。
主要发现
- 高效疗法使首次复发风险降低54%(校正HR 0.46;95%CI 0.31-0.67;P<.001),且持续5年。
- MRI活动确认高效疗法优于中等疗效疗法(校正OR 0.34;95%CI 0.18-0.66;P=.001)。
- 中等疗效疗法2年停药风险是高效疗法的近6倍(HR 5.97;95%CI 2.92-12.20)。
- 初始治疗与EDSS进展或高等教育获得无关(校正OR 0.51;95%CI 0.24-1.10;P=.09)。
关键数值与推荐
- 高效疗法组与中等疗效疗法组相比,首次复发风险降低54%(校正HR 0.46;95%CI 0.31-0.67;P<.001)。
- 高效疗法组与中等疗效疗法组相比,MRI活动校正OR 0.34(95%CI 0.18-0.66;P=.001)。
- 中等疗效疗法组2年停药风险HR 5.97(95%CI 2.92-12.20),高于高效疗法组。
- 初始治疗与EDSS进展或高等教育获得无显著关联(校正OR 0.51;95%CI 0.24-1.10;P=.09)。
临床怎么用
- 作者认为,儿童期起病多发性硬化可优先考虑初始高效疗法,但需要长期安全性研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus. OBJECTIVE: To assess the real-world association of HET as an index treatment compared with MET with disease activity. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit. The median follow-up was 5.8 years. A total of 36 French MS centers participated in the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Of the total participants in OFSEP, only treatment-naive children with relapsing-remitting POMS who received a first HET or MET before adulthood and at least 1 follow-up clinical visit were included in the study. All eligible participants were included in the study, and none declined to participate. EXPOSURE: HET or MET at treatment initiation. MAIN OUTCOMES AND MEASURES: The primary outcome was the time to first relapse after treatment. Secondary outcomes were annualized relapse rate (ARR), magnetic resonance imaging (MRI) activity, time to Expanded Disability Status Scale (EDSS) progression, tertiary education attainment, and treatment safety/tolerability. An adapted statistical method was used to model the logarithm of event rate by penalized splines of time, allowing adjustment for effects of covariates that is sensitive to nonlinearity and interactions. RESULTS: Of the 3841 children (5.2% of 74 367 total participants in OFSEP), 530 patients (mean [SD] age, 16.0 [1.8] years; 364 female [68.7%]) were included in the study. In study patients, both treatment strategies were associated with a reduced risk of first relapse within the first 2 years. HET dampened disease activity with a 54% reduction in first relapse risk (adjusted hazard ratio [HR], 0.46; 95% CI, 0.31-0.67; P < .001) sustained over 5 years, confirmed on MRI activity (adjusted odds ratio [OR], 0.34; 95% CI, 0.18-0.66; P = .001), and with a better tolerability pattern than MET. The risk of discontinuation at 2 years was 6 times higher with MET (HR, 5.97; 95% CI, 2.92-12.20). The primary reasons for treatment discontinuation were lack of efficacy and intolerance. Index treatment was not associated with EDSS progression or tertiary education attainment (adjusted OR, 0.51; 95% CI, 0.24-1.10; P = .09). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that compared with MET, initial HET in POMS was associated with a reduction in the risk of first relapse with an optimal outcome within the first 2 years and was associated with a lower rate of treatment switching and a better midterm tolerance in children. These findings suggest prioritizing initial HET in POMS, although long-term safety studies are needed.
引用
- Benallegue N, Rollot F, Wiertlewski S, et al. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2024. PMID: 38345791. doi:10.1001/jamaneurol.2023.5566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。